Patents Assigned to Ribotargets
-
Patent number: 6573045Abstract: The invention relates to a solution-based assay for identifying RNA binding compounds, based on competition. The assay comprises a reporter molecule carrying a fluorescent or chromogenic group that can form a one-to-one complex with an RNA target molecule carrying a second fluorescent or chromogenic group in such a way that the two groups are in sufficient proximity for fluorescence resonance energy transfer and/or quenching to take place. Addition of a compound-to-be-tested prevents formation of the complex and thereby increases the fluorescence of the RNA target and/or reporter molecules relative to the signal obtained in the absence of the test compound. The invention also provides for quantitative screening methods and kits are also included.Type: GrantFiled: June 3, 1999Date of Patent: June 3, 2003Assignee: Ribotargets, Ltd.Inventors: Jonathan Karn, Catherine Denise Prescott
-
Patent number: 6395891Abstract: The invention relates to an isolated nucleic acid comprising two operatively linked binding sites for HIV Rev protein, the sites comprising a nucleation motif and an oligomerization motif, wherein the nucleic acid binds Rev protein monomers with a higher degree of cooperativity than wild-type RRE.Type: GrantFiled: September 11, 1998Date of Patent: May 28, 2002Assignee: RiboTargets LimitedInventors: Jonathan Karn, Rodney Warren Zemmel, Peter Jonathan Gasking Butler, Roger K. Craig, Alistair Simpson Irvine
-
Patent number: 6316194Abstract: The invention provides a method for determining whether a test compound binds to a target RNA, the method comprising the steps of: (a) contacting the test compound with a pair of indicator molecules comprising an antimicrobial labelled with a donor group or an acceptor group and the target RNA labelled with a complementary acceptor or donor group, the pair being capable of binding to each other in an orientation that permits the donor group to come into sufficient proximity to the acceptor group to permit fluorescent resonance energy transfer and/or quenching to take place; and (b) measuring the fluorescence of the target RNA and/or the antimicrobial in the presence of the test compound and comparing this value to the fluorescence of a standard.Type: GrantFiled: December 16, 1999Date of Patent: November 13, 2001Assignee: RibotargetsInventors: Jonathan Karn, David Justin Charles Knowles, Alastair Iain Hamilton Murchie, Georg Friedrich Lentzen
-
Patent number: 6225045Abstract: The invention relates to an isolated nucleic acid comprising two operatively linked binding sites for HIV Rev protein, the sites comprising a nucleation motif and an oligomerization motif, wherein the nucleic acid binds Rev protein monomers with a higher degree of co-operativity than wild-type RRE.Type: GrantFiled: April 15, 1997Date of Patent: May 1, 2001Assignee: Ribotargets, Ltd.Inventors: Jonathan Karn, Rodney Warren Zemmel, Peter Jonathan Gasking Butler, Roger K. Craig, Alistair Simpson Irvine
-
Patent number: 6153382Abstract: A synthetic molecule comprises at least one oligonucleotide comprising an RNA binding sequence or sequences corresponding to the site bound by the HIV protein rev and capable of binding ot rev within cells. The binding sequence or sequences, by binding with rev within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients infected with HIV. The invention also provides an assay for identifying that inhibit rev binding.Type: GrantFiled: September 15, 1997Date of Patent: November 28, 2000Assignee: Ribotargets, Ltd.Inventors: Jonathan Karn, Michael John Gait, Shaun Heaphy, Colin Dingwall
-
Patent number: 6114109Abstract: A synthetic molecule comprises at least one oligonucleotide, comprising and RNA binding sequence or sequences corresponding to the site bound by the HIV protein tat and capable of binding to tat within cells. The binding sequence or sequences, by binding tat within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients affected with HIV. The invention also provides an assay for identifying compounds that inhibit tat binding.Type: GrantFiled: May 22, 1998Date of Patent: September 5, 2000Assignee: RiboTargets, Ltd.Inventors: Jonathan Karn, Michael J. Gait, Shaun Heaphy, Colin Dingwall
-
Patent number: 5821046Abstract: A synthetic molecule comprising an RNA binding sequence or sequences corresponding to the site bound by the HIV protein tat and capable of binding to tat within cells. The binding sequence or sequences, by binding tat within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients affected with HIV. The invention also provides an assay for identifying compounds that inhibit tat binding.Type: GrantFiled: October 10, 1995Date of Patent: October 13, 1998Assignee: RiboTargets Holdings PLCInventors: Jonathan Karn, Michael John Gait, Shaun Heaphy, Colin Dingwall